Grade 6 (£26,243 - £32,236) or Grade 7 (£32,236 - £39,609) depend upon experience
Biological Chemistry and Drug Discovery
We are looking for a highly motivated and experienced malaria or cryptosporidiosis biologist to join our drug discovery group. The appointee will be involved in leading the biology aspects of a portfolio of drug discovery projects for malaria and cryptosporidiosis and integrating them with the chemistry, computational chemistry and pharmacokinetic aspects of the projects.
The Drug Discovery Unit (DDU) (see http://www.drugdiscovery.dundee.ac.uk) is a fully integrated drug discovery operation based within a world class Life Sciences research environment. Its remit is to complement BioPharma activities by tackling both neglected diseases (Trypanosomiasis, Leishmaniasis and Malaria) and early stage small molecule validation of novel targets & mechanisms across a range of potential therapeutic areas.
Professor Alessio Ciulli’s laboratory is seeking a postdoctoral researcher to undertake research in collaboration with one of the leading pharmaceutical companies supporting the Division of Signal Transduction Therapy (DSTT).
Hannah Tovell an Alessi lab PhD student working closely with the Ciulli lab has published an improved HaloPROTAC method to induce post–translational knockdown of endogenous proteins.
This approach makes use of CRISPR/Cas9 genome editing technology to introduce a Halo tag onto the N or C terminus of any desired target protein that can then be targeted for degradation by a HaloPROTAC probe (see Figure).
The Drug Discovery Unit (DDU) (see http://www.drugdiscovery.dundee.ac.uk) is a fully integrated drug discovery operation based within a world class life sciences research environment. Its remit is to complement Biopharma activities by tackling both neglected diseases (leishmaniasis, malaria, tuberculosis) and validating novel drug targets across a range of therapeutic areas.